Sjogren’s disease: two drugs with positive trials Sjogren’s disease: two drugs with positive trials After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost! At #ACR25, not one but two drugs presented their efficacy https://t.co/kTTdZnVUtj

RETREAT study was a 12 wk RCT of Tai Chi in 178 knee OA pts Rx w/ online OA info vs same plus free web based tai chi video program. Tai Chi group had signif improved knee pain (−2.7 v -1.2); (−12 v −6.9) & achieved a minimal pain & function (73% v 47%); and Its free! https://t.co/WLzQ9YHrcu

Off the Shelf: CAR-T Dr. Akhil Sood reports on abstract 0663 (iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy) presented at#ACR25. https://t.co/mj4b5cCInC https://t.co/s34atFCMlx

AI in Fellow Recruitment: A New Dawn in Medical Education? Drs. Mrinalini Dey and Bharat Kumar abstract 2174 (Using Natural Language Processing to Identify Character Strengths in Rheumatology Fellowship Candidate Applications: A Feasibility Study) presented at #ACR25. https://t.co/gGx4zZlfAm

Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA At #ACR25, abstract 1039, "Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis," highlights the critical economic and ethical dimensions of CAR-T cell therapy in autoimmune https://t.co/Rci0dL7THj

📖➡️The GCA story continues with new data from a Phase 3 trial of a JAKi, sponsored by AbbVie Medical Affairs + Health Impact. 🔥 Hot off the press from ACR 2025, hear Dr. Dua & Dr. Boone discuss the latest data in GCA. https://t.co/Wuu7xe5Xbl https://t.co/mnTiXmChHp

Are we putting the CAR-T before the horse? CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure. https://t.co/gF9FXjAZ7F

B Cell Depletion: Check the Lymph Node Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25. https://t.co/bvZMGWNzfe https://t.co/dB6iQlgoYx

900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the https://t.co/o7BaWjS4HB

Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA At #ACR25, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in https://t.co/49J2X48i4E

IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and https://t.co/7awBk16ZrQ